Yervoy Research This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Treatment of Metastatic Renal Cell Carcinoma with Checkpoint Inhibitors in Clinical Practice in the Volga-Ural Region of the Eurasian Continent
CONCLUSION: In this single-center clinical study, we discuss the results of using nivolumab as mono-therapy and the combination of nivolumab with ipilimumab in metastatic renal parenchyma cancer patients.PMID:38037838 | DOI:10.2174/0113816128262498231122072050 (Source: Current Pharmaceutical Design)
Source: Current Pharmaceutical Design - December 1, 2023 Category: Drugs & Pharmacology Authors: Radmir R Rakhimov Aleksandr V Sultanbaev Adel A Izmailov Konstantin V Menshikov Vadim M Zabelin Albert A Izmailov Gulshat R Gilyazova Svetlana M Izmailova Ksenia S Bakhtiyarova Izmailova Angelina Irina R Gilyazova Source Type: research

MSR143 Extending Bayesian Evidence Synthesis to Include Historical Trial Data for Improved Survival Extrapolations from Early Data Cuts in Metastatic Non-Small Cell Lung Cancer (mNSCLC)
Survival extrapolations from na ïve standard parametric models (SPMs) can be highly unreliable when fitting to early cuts of study data, even for short-term projections. Utilizing external data is therefore desirable, but predictions can then be dependent on the data sources and implementation method. Here, we extend the Bayesian multi-parameter evidence synthesis (B-MPES) framework to incorporate historical trial data and fit a B-MPES model to 1-year data from CheckMate 9LA, which compares nivolumab plus ipilimumab plus two cycles of chemotherapy (NIVO+IPI+CHEMO) versus four cycles of CHEMO in first-line mNSCLC. (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: D. Sharpe, G. Yates, L. Garc ía-Fernández, Y. Yuan, A. Lee, M.A. Chaudhary Source Type: research

HTA14 Expanding the HTA Cost-Effectiveness Analyses for CheckMate 9LA: Nivolumab Plus Ipilimumab Plus Chemotherapy As First-Line Strategy for Non-Small Cell Lung Cancer
The evidence required by health technology appraisal (HTA) agencies to assess the cost-effectiveness of new therapies is often limited to quality-adjusted survival and direct costs. The inclusion of additional elements of value meaningful to patients is often excluded by HTAs. A limited number of studies have been conducted to assess the impact of including novel value elements in HTA cost-effectiveness analyses (CEAs). (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: I. Orsini, M. Venkatachalam, Y. Yuan, A. Lee, J.R. Penrod Source Type: research

EE692 Cost-Effectiveness of Nivolumab (NIVO) and NIVO in Combination With Ipilimumab (IPI) in First-Line Treatment of Advanced Melanoma in Colombia: Analysis Using 78-Month Overall Survival From CheckMate 067
The objective of this study was to evaluate the cost-effectiveness of NIVO or NIVO+IPI compared to current therapeutic alternatives in first-line treatment of patients with advanced melanoma in Colombia from a healthcare payer perspective, using 78-month survival data from the CheckMate 067 Phase III trial. (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: R. Kendall, V. Barco, A. Sharma, L. McDonald, J. Garcia Perlaza, T. Baker Source Type: research

EE206 Clinical and Economic Evaluation of Atezolizumab + Vemurafenib + Cobimetinib Combination in Treatment of Adult Patients with Metastatic Braf-Positive Melanoma
The aim of the study was to conduct a pharmacoeconomic evaluation of the atezolizumab, vemurofenib and cobimetinib (ATZ+VM+COB) combination and the nivolumab and ipilimumab (NIVO+IPI) combination for the treatment of BRAF-confirmed metastatic melanoma in adult patients. (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: E. Makarova, I. Krysanov, V. Ermakova, D.V. Kurkin Source Type: research

EE203 Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab Versus Other First-Line Therapies for Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer in the United States
To evaluate the cost-effectiveness of nivolumab plus ipilimumab (NIVO+IPI) versus platinum-doublet chemotherapy (PDC) and other immunotherapies used as first-line treatment for stage IV or recurrent non-small cell lung cancer (NSCLC) in the United States (US) from a third-party payer perspective. (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: A. Libanore, A. Lee, B. Baginska, M.A. Chaudhary, J. Maervoet, S. Ray, Y. Yuan Source Type: research

Improving visual acuity with nivolumab plus ipilimumab plus two cycles of chemotherapy following a diagnosis of lung adenocarcinoma with choroidal metastasis: A case report and literature review
In this report, a lung cancer patient with choroidal metastasis was treated with nivolumab plus ipilimumab combined with two cycles of platinum-based chemotherapy, resulting in a reduction of the primary tumour and choroidal metastases, and an improvement of visual acuity and quality of life. AbstractA 75-year-old woman presented at our hospital with bilateral visual impairment. Ophthalmological examination revealed multiple choroidal tumours. Chest computed tomography revealed a tumour shadow in the right lower lobe and multiple lymph node metastases in the mediastinum and pulmonary hilum. Following a detailed examination...
Source: Respirology Case Reports - November 30, 2023 Category: Respiratory Medicine Authors: Takahiro Matsuyama, Masashi Oniwa, Kentaro Tsuruzono, Shunsuke Yasuda, Mikiko Yone, Yuya Tomioka, Akifumi Uchida, Hideo Mitsuyama, Shingo Kubota, Takayuki Suetsugu, Keiko Mizuno, Hiromasa Inoue Tags: CASE REPORT Source Type: research

Outcome and treatment-related adverse events of combined immune checkpoint inhibition with flipped dosing in a real-world cohort of 79 patients with metastasized melanoma
DiscussionThe results of our study correspond very well to the results of the CheckMate 511 study (2-year OS: 65%, grade 3-4 immune-related side effects: 35%). Combined ICI with ipilimumab 1 mg/kg bw and nivolumab 3 mg/kg bw seems to be an equally effective but better-tolerated therapy regimen for metastasized melanoma patients, also in a real-world cohort. (Source: Frontiers in Oncology)
Source: Frontiers in Oncology - November 30, 2023 Category: Cancer & Oncology Source Type: research

T-Cell Receptor Repertoire as a Predictor of Immune-Related Adverse Events in Renal Cell Carcinoma
Curr Issues Mol Biol. 2023 Nov 9;45(11):8939-8949. doi: 10.3390/cimb45110561.ABSTRACTImmune checkpoint inhibitors (ICIs) are effective in treating renal cell carcinoma (RCC) but can also cause immune-related adverse events (irAEs). The relationship between irAEs and the T-cell receptor (TCR) repertoire in RCC patients treated with ICIs remains unclear. We analyzed the relationship between the severity and diversity of irAEs and the TCR repertoire in RCC patients who received dual checkpoint inhibitors (ipilimumab + nivolumab). The TCRβ (TRB) repertoires were characterized in peripheral blood samples from six patients with...
Source: Current Issues in Molecular Biology - November 24, 2023 Category: Molecular Biology Authors: Takuro Kobayashi Masayoshi Nagata Yoshihiro Ikehata Yuki Nagashima Naoya Nagaya Yan Lu Shigeo Horie Source Type: research

T-Cell Receptor Repertoire as a Predictor of Immune-Related Adverse Events in Renal Cell Carcinoma
Curr Issues Mol Biol. 2023 Nov 9;45(11):8939-8949. doi: 10.3390/cimb45110561.ABSTRACTImmune checkpoint inhibitors (ICIs) are effective in treating renal cell carcinoma (RCC) but can also cause immune-related adverse events (irAEs). The relationship between irAEs and the T-cell receptor (TCR) repertoire in RCC patients treated with ICIs remains unclear. We analyzed the relationship between the severity and diversity of irAEs and the TCR repertoire in RCC patients who received dual checkpoint inhibitors (ipilimumab + nivolumab). The TCRβ (TRB) repertoires were characterized in peripheral blood samples from six patients with...
Source: Mol Biol Cell - November 24, 2023 Category: Molecular Biology Authors: Takuro Kobayashi Masayoshi Nagata Yoshihiro Ikehata Yuki Nagashima Naoya Nagaya Yan Lu Shigeo Horie Source Type: research